Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 855-580-5 | CAS number: 102089-75-8
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Acute Toxicity: oral
Administrative data
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 12 February - 3 March 2020
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- study well documented, meets generally accepted scientific principles, acceptable for assessment
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 020
- Report date:
- 2020
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 420 (Acute Oral Toxicity - Fixed Dose Method)
- GLP compliance:
- no
- Test type:
- fixed dose procedure
- Limit test:
- yes
Test material
- Reference substance name:
- tert-butyl N-[(1R)-2-(methanesulfonyloxy)-1-phenylethyl]carbamate
- EC Number:
- 855-580-5
- Cas Number:
- 102089-75-8
- Molecular formula:
- C14H21NO5S
- IUPAC Name:
- tert-butyl N-[(1R)-2-(methanesulfonyloxy)-1-phenylethyl]carbamate
- Test material form:
- solid: particulate/powder
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- not specified
- Details on test animals or test system and environmental conditions:
- A total of 5 animals were used for each dose level. This includes the animal from the sighting study administered the same dose and an additional four animals. Food was removed overnight prior to dosing and returned approximately 2-3 hours after dosing. Then, food was available ad libitum. Body weights were observed on days 1, 7, and 14 and clinical observations were made on days 1-14.
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- not specified
- Details on oral exposure:
- The test material was administed as a single dose via oral gavage with a 14 day observation period according to OECD 420 Acute Oral Toxicity - Fixed Dose Procedure. The formulation was composed of 0.5% hydroxpropylmethylcellulose (HPMC). The dose volume was 10 mL/kg (all concentrations).
- Doses:
- Sighting study: 300 mgkg, 2,000 mg/kg
Main Study: 2,000 mg/kg - No. of animals per sex per dose:
- Not specified
- Control animals:
- not specified
- Details on study design:
- Sighting Study: The purpose of the sighting study was to determine the starting dose for the main study. The test article was administered to one animal at a time in a sequential manner with at least 24 hours between the dosing of each animal. Animals are maintained for a period of at least 14 days. Dose levels are fixed at 5, 50, 300, and 2,000 mg/kg. The first animal was dosed at a level expected to produce toxicity based on available in vivo or in vitro data; or at 300 mg/kg when no toxicity information is available. Depending on signs of toxicity, the next animal was dosed at the next higher or next lower dose level. Dosing continued until a dose level for the main test was determined determined or death was seen at the lowest fixed dose.
Main Test: The main test dose was determined by the sighting study. A total of 5 animals were used for each dose level. This included the animal from the sighting study administered the same dose and an additional four animals. The course of the study depended on the response of the animals at the dose level for the main test; either the testing was stopped and the appropriate hazard classification class was assigned; or the tesitng continued at a higher fixed dose level; or testing continued at a lower fixed dose level. If additional dose levels were tested, the time interval between them was determined by the onset, duration, and severity of toxic signs.
After dosing, the animals were returned to their cages and supplied with feed and water ad libitum. Clinical observations were made at least once during the first 30 minutes with special attention given during the first 6 hours and then at least daily for a period of 14 days. The frequency was determined by the response of the test animals to the treatment. However, the duration of observation was not fixed rigidly. It was determined by the toxic reactions, rate of onset and length of recovery period, and was therefore be extended when considered necessary. The time at which signs of toxicity appeared and disappeared and the time of death were important, especially if there was a tendency for deaths to be delayed. All observations were recorded, and individual records were maintained for each animal. Cageside observations included changes in skin and fur, eyes and mucous membranes, and also respiratory, circulatory, autonomic, and central nervous system, and somatomotor activity and behavior pattern. Particular attention was directed to observations of tremors, convulsions, salivation, diarrhea, lethargy, sleep and coma. The time of death was recorded as precisely as possible. Moribund animals that were killed for humane reasons were considered in the same way as animals that died on test.
Animals were weighed weekly and at the end of the observation period and then were sacrificed by exsanguination under deep anesthesia with intraperitoneal ketamine and xylazine. Changes in weights were calculated and recorded when survival exceeded one day. Any animal found dead was necropsied as soon as possible, but in no case later than 12 hours after discovery. A gross necropsy was performed on all animals whether found dead, sacrified in extremis, or sacrified at the end of the study and all gross pathological changes were recorded.
An evaluation of acute toxicity data included the relationship, if any, between the animals exposed to the test article and the incidence and severity of all abnormalities, including behavioral and clinical abnormalities, gross lesions, body weigh changes, effects on mortality, and any other toxic effects.
Results and discussion
- Preliminary study:
- Animal 1002 was dosed at 300 mg/kg of the test material as there was no information available on toxicity. Starting approximately 30 minutes after dosing clinical signs including piloerection and mildly decreased activity were observed, which lasted until the 4 h timepoint. In addition, animal 1002 showed increased consumption of the wooden bedding pellets one hour after dosing which might have been a sign of distress or abdominal pain but could also be related to the stress caused by the procedure itself, especially considering the fasting and the single housing. At the 3 hour observation point, walking on toes was obseved in this animal. To gain more information on the toxicological profile of the test material, animal 1004 was dosed the next day at the next higher dose of 2,000 mg/kg. Approximately 20 minutes after dosing mildly decreased activity was observed. Starting approximately 2 hours after application, clinical signs including partial palpebral closure, pilo-erection, hunched posture and decreased activity were observed, which lasted until the 6 hour timepoint. All clinical signs in animal 1004 were resolved 24 hours after dosing and the animal appeared normal. Based on the observations 2,000 mg/kg was chosen for the main study.
Four additional animals (1006, 1008, 1010, and 1012) were dosed at 2,000 mg/kg of the test material
Effect levels
- Key result
- Sex:
- not specified
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 mg/kg bw
- Based on:
- test mat.
- Mortality:
- None
- Clinical signs:
- other: All four animals showed clinical signs of decreaesd activity and rough hair starting 1 hour post dose. Animals 1006, 1008, and 1012 also showed piloerection and partial palebral closure. All clinical signs were reslved 4 hours post dose.
- Gross pathology:
- There were no findings during gross necropsy in any of the main animals at the end of the study; all tissues appeared normal.
Applicant's summary and conclusion
- Interpretation of results:
- GHS criteria not met
- Conclusions:
- The test item was determined to have an estimated LD50>2,000 mg/kg and was therefore classified as a Hazard Category 5 according to GHS, but because category 5 is not implemented in the EU, GHS criteria was considered to be not met.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.